Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PRKAG2-ACTR3C

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PRKAG2-ACTR3C
	FusionPDB ID: 68632
	FusionGDB2.0 ID: 68632
		Hgene	Tgene
	Gene symbol	PRKAG2	ACTR3C
	Gene ID	51422	653857
	Gene name	protein kinase AMP-activated non-catalytic subunit gamma 2	actin related protein 3C
	Synonyms	AAKG\|AAKG2\|CMH6\|H91620p\|WPWS	ARP11
	Cytomap	7q36.1	7q36.1
	Type of gene	protein-coding	protein-coding
	Description	5'-AMP-activated protein kinase subunit gamma-2AMPK subunit gamma-2epididymis secretory sperm binding proteinprotein kinase, AMP-activated, gamma 2 non-catalytic subunit	actin-related protein 3CARP3 actin related protein 3 homolog Cactin-related Arp11actin-related protein 11
	Modification date	20200320	20200313
	UniProtAcc	.	Q9C0K3 Main function of 5'-partner protein: FUNCTION: May play a role in the suppression of metastatic potential in lung adenoma carcinoma cells. {ECO:0000269\|PubMed:11162478}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000392801, ENST00000287878, ENST00000433631, ENST00000492843, ENST00000418337, ENST00000461529,	ENST00000252071, ENST00000539352,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	16 X 11 X 10=1760	6 X 5 X 3=90
	# samples	21	6
	** MAII score	log2(21/1760*10)=-3.06711419585854 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(6/90*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PRKAG2 [Title/Abstract] AND ACTR3C [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PRKAG2 [Title/Abstract] AND ACTR3C [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PRKAG2(151372506)-ACTR3C(149946143), # samples:2
Anticipated loss of major functional domain due to fusion event.	PRKAG2-ACTR3C seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRKAG2-ACTR3C seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRKAG2-ACTR3C seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. PRKAG2-ACTR3C seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. PRKAG2-ACTR3C seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. PRKAG2-ACTR3C seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PRKAG2	GO:0006469	negative regulation of protein kinase activity	17255938

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:151372506/chr7:149946143)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PRKAG2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ACTR3C (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000287878	PRKAG2	chr7	151372506	-	ENST00000252071	ACTR3C	chr7	149946143	-	1653	1189	493	1257	254
ENST00000287878	PRKAG2	chr7	151372506	-	ENST00000539352	ACTR3C	chr7	149946143	-	1653	1189	493	1257	254
ENST00000433631	PRKAG2	chr7	151372506	-	ENST00000252071	ACTR3C	chr7	149946143	-	1046	582	750	289	153
ENST00000433631	PRKAG2	chr7	151372506	-	ENST00000539352	ACTR3C	chr7	149946143	-	1046	582	750	289	153
ENST00000492843	PRKAG2	chr7	151372506	-	ENST00000252071	ACTR3C	chr7	149946143	-	1097	633	801	340	153
ENST00000492843	PRKAG2	chr7	151372506	-	ENST00000539352	ACTR3C	chr7	149946143	-	1097	633	801	340	153

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000287878	ENST00000252071	PRKAG2	chr7	151372506	-	ACTR3C	chr7	149946143	-	0.33794877	0.6620512
ENST00000287878	ENST00000539352	PRKAG2	chr7	151372506	-	ACTR3C	chr7	149946143	-	0.33794877	0.6620512
ENST00000433631	ENST00000252071	PRKAG2	chr7	151372506	-	ACTR3C	chr7	149946143	-	0.45865238	0.5413476
ENST00000433631	ENST00000539352	PRKAG2	chr7	151372506	-	ACTR3C	chr7	149946143	-	0.45865238	0.5413476
ENST00000492843	ENST00000252071	PRKAG2	chr7	151372506	-	ACTR3C	chr7	149946143	-	0.55577713	0.4442228
ENST00000492843	ENST00000539352	PRKAG2	chr7	151372506	-	ACTR3C	chr7	149946143	-	0.55577713	0.4442228

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRKAG2-ACTR3C

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PRKAG2	chr7	151372506	ACTR3C	chr7	149946143	1189	232	PLASPTHYAPSKAMEQIPLSYPQGHG

Top

Potential FusionNeoAntigen Information of PRKAG2-ACTR3C in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PRKAG2-ACTR3C_151372506_149946143.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:18	HYAPSKAM	0.9806	0.7243	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:10	HYAPSKAM	0.9367	0.6101	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:37	HYAPSKAM	0.8748	0.6386	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:01	SKAMEQIPL	0.9979	0.9162	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:24	THYAPSKAM	0.9978	0.6115	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:01	THYAPSKAM	0.997	0.9276	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:10	THYAPSKAM	0.9957	0.642	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:13	SKAMEQIPL	0.9946	0.946	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:06	THYAPSKAM	0.9939	0.872	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:13	THYAPSKAM	0.9901	0.9487	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B38:02	THYAPSKAM	0.9876	0.9719	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:37	THYAPSKAM	0.9857	0.6906	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B38:01	THYAPSKAM	0.9856	0.9679	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:01	AMEQIPLSY	0.9824	0.7975	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:25	AMEQIPLSY	0.9628	0.8657	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B14:01	THYAPSKAM	0.9451	0.8835	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B14:02	THYAPSKAM	0.9451	0.8835	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:10	SKAMEQIPL	0.9328	0.5627	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:18	THYAPSKAM	0.9132	0.8385	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:02	AMEQIPLSY	0.9013	0.8872	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:03	THYAPSKAM	0.866	0.8763	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:03	APSKAMEQI	0.7136	0.7853	8	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:03	AMEQIPLSY	0.4629	0.6669	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:18	AMEQIPLSY	0.3864	0.616	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:10	THYAPSKAM	0.1646	0.573	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-A32:13	AMEQIPLSY	0.0759	0.8293	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B48:01	THYAPSKAM	0.0185	0.6907	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:01	KAMEQIPLSY	0.9999	0.8082	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:25	KAMEQIPLSY	0.9998	0.8275	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:02	KAMEQIPLSY	0.9993	0.8458	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B57:01	KAMEQIPLSY	0.9992	0.8957	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:17	KAMEQIPLSY	0.999	0.7841	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B58:02	KAMEQIPLSY	0.9968	0.7442	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B58:01	KAMEQIPLSY	0.9958	0.7326	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:16	KAMEQIPLSY	0.9944	0.6047	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:01	KAMEQIPLSY	0.9938	0.7342	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:03	KAMEQIPLSY	0.9933	0.635	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B57:03	KAMEQIPLSY	0.9846	0.9012	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:05	KAMEQIPLSY	0.9519	0.5047	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:10	THYAPSKAME	0.9394	0.5908	5	15
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:37	THYAPSKAME	0.7808	0.594	5	15
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-A32:13	KAMEQIPLSY	0.4917	0.749	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:05	SPTHYAPSKAM	0.9998	0.5521	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:02	SPTHYAPSKAM	0.9998	0.5978	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:10	SPTHYAPSKAM	0.9998	0.6451	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:03	SKAMEQIPLSY	0.9859	0.6317	10	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:24	SPTHYAPSKAM	0.9648	0.6056	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:03	SPTHYAPSKAM	0.9452	0.6652	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:18	SPTHYAPSKAM	0.8465	0.5097	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:01	SPTHYAPSKAM	0.8217	0.8254	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B82:01	SPTHYAPSKAM	0.7858	0.5056	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:02	SPTHYAPSKAM	0.7485	0.8133	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:04	SPTHYAPSKAM	0.7485	0.8133	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B38:02	SPTHYAPSKAM	0.5338	0.9355	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:80	HYAPSKAM	0.9835	0.9744	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:67	HYAPSKAM	0.9835	0.9744	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:09	SKAMEQIPL	0.998	0.6285	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:09	THYAPSKAM	0.9974	0.7813	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:12	THYAPSKAM	0.9967	0.9312	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:05	SKAMEQIPL	0.9952	0.9095	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:05	THYAPSKAM	0.9873	0.9126	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:07	AMEQIPLSY	0.9267	0.5339	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:12	APSKAMEQI	0.9102	0.5177	8	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:05	AMEQIPLSY	0.9082	0.7933	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:21	AMEQIPLSY	0.8859	0.8714	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:31	AMEQIPLSY	0.8294	0.8085	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:95	THYAPSKAM	0.7538	0.7626	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:05	THYAPSKAM	0.7485	0.9765	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:27	THYAPSKAM	0.7327	0.9674	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:29	THYAPSKAM	0.6555	0.9531	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:13	THYAPSKAM	0.6212	0.9559	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:04	AMEQIPLSY	0.6104	0.7845	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:46	THYAPSKAM	0.6093	0.9311	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:08	THYAPSKAM	0.6092	0.8417	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:19	THYAPSKAM	0.5502	0.8534	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:67	THYAPSKAM	0.5094	0.9656	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:80	THYAPSKAM	0.5094	0.9656	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:10	THYAPSKAM	0.4151	0.9776	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:21	THYAPSKAM	0.3811	0.9338	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B14:03	THYAPSKAM	0.3447	0.8666	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:10	APSKAMEQI	0.2433	0.9256	8	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C12:16	THYAPSKAM	0.2406	0.9685	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C03:14	AMEQIPLSY	0.1984	0.9731	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B73:01	THYAPSKAM	0.0033	0.8109	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:07	KAMEQIPLSY	0.9996	0.5527	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:21	KAMEQIPLSY	0.9991	0.8039	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C15:04	KAMEQIPLSY	0.9978	0.8529	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:05	KAMEQIPLSY	0.9975	0.7476	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:31	KAMEQIPLSY	0.9938	0.7575	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:04	KAMEQIPLSY	0.9934	0.8028	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C12:04	KAMEQIPLSY	0.9673	0.9856	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C06:03	KAMEQIPLSY	0.967	0.988	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C12:12	KAMEQIPLSY	0.9668	0.9319	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C03:14	KAMEQIPLSY	0.9636	0.9643	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C01:17	YAPSKAMEQI	0.9508	0.9451	7	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C01:30	YAPSKAMEQI	0.9235	0.9597	7	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:12	APSKAMEQIPL	0.9957	0.5033	8	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:04	SPTHYAPSKAM	0.9908	0.519	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:12	SPTHYAPSKAM	0.9839	0.7341	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B42:02	SPTHYAPSKAM	0.9745	0.6551	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B42:01	SPTHYAPSKAM	0.9724	0.6498	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:10	SPTHYAPSKAM	0.836	0.8393	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:09	SPTHYAPSKAM	0.8141	0.622	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:12	SPTHYAPSKAM	0.7485	0.8133	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:05	SPTHYAPSKAM	0.4802	0.8085	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:17	HYAPSKAM	0.9909	0.9798	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:02	HYAPSKAM	0.9835	0.9744	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C06:06	HYAPSKAM	0.9768	0.9957	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C14:02	HYAPSKAM	0.9697	0.9729	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C14:03	HYAPSKAM	0.9697	0.9729	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:09	HYAPSKAM	0.6344	0.6636	6	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:31	SKAMEQIPL	0.9979	0.9177	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:02	SKAMEQIPL	0.9979	0.947	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:02	THYAPSKAM	0.9966	0.9493	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:31	THYAPSKAM	0.9939	0.9287	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B38:05	THYAPSKAM	0.9856	0.9679	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:50	AMEQIPLSY	0.9843	0.8863	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:12	AMEQIPLSY	0.9842	0.7491	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:27	AMEQIPLSY	0.9826	0.7921	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:34	AMEQIPLSY	0.9824	0.7975	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:33	AMEQIPLSY	0.9824	0.7975	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:125	AMEQIPLSY	0.9824	0.7975	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:135	AMEQIPLSY	0.9806	0.7645	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:11	AMEQIPLSY	0.9624	0.7382	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:39	AMEQIPLSY	0.9622	0.7479	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:08	AMEQIPLSY	0.9591	0.7325	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:09	THYAPSKAM	0.9501	0.7931	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:09	SKAMEQIPL	0.9237	0.6025	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:35	AMEQIPLSY	0.9126	0.7172	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:20	AMEQIPLSY	0.9085	0.8591	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:24	AMEQIPLSY	0.8672	0.7145	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:28	AMEQIPLSY	0.8629	0.852	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:20	AMEQIPLSY	0.826	0.8693	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B48:02	THYAPSKAM	0.8248	0.9182	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:53	AMEQIPLSY	0.7934	0.7419	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:17	THYAPSKAM	0.7598	0.9729	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C03:67	THYAPSKAM	0.7417	0.986	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:22	THYAPSKAM	0.7377	0.7424	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:01	THYAPSKAM	0.7322	0.7733	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:11	SKAMEQIPL	0.7287	0.6757	10	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:13	APSKAMEQI	0.6729	0.7961	8	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B39:11	THYAPSKAM	0.6235	0.7802	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:02	THYAPSKAM	0.5094	0.9656	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:13	AMEQIPLSY	0.4896	0.5636	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C03:02	AMEQIPLSY	0.4572	0.9675	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B18:04	AMEQIPLSY	0.4079	0.9221	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:54	AMEQIPLSY	0.4012	0.7194	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B48:02	AMEQIPLSY	0.3951	0.8458	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:04	THYAPSKAM	0.374	0.9555	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C07:17	AMEQIPLSY	0.3481	0.9687	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B67:01	APSKAMEQI	0.2912	0.7815	8	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-A32:01	AMEQIPLSY	0.212	0.848	12	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C06:06	THYAPSKAM	0.1898	0.994	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C06:08	THYAPSKAM	0.0596	0.9945	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C14:02	THYAPSKAM	0.0569	0.9699	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C14:03	THYAPSKAM	0.0569	0.9699	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C06:02	THYAPSKAM	0.0467	0.9951	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C06:17	THYAPSKAM	0.0467	0.9951	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:68	THYAPSKAM	0.0461	0.7349	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:54	THYAPSKAM	0.0444	0.9135	5	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:27	KAMEQIPLSY	0.9999	0.848	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:34	KAMEQIPLSY	0.9999	0.8082	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:33	KAMEQIPLSY	0.9999	0.8082	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:125	KAMEQIPLSY	0.9999	0.8082	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:39	KAMEQIPLSY	0.9998	0.7148	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:135	KAMEQIPLSY	0.9998	0.8016	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:08	KAMEQIPLSY	0.9997	0.7324	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:11	KAMEQIPLSY	0.9997	0.742	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:50	KAMEQIPLSY	0.9996	0.8635	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:43	KAMEQIPLSY	0.9996	0.7344	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:35	KAMEQIPLSY	0.9996	0.7528	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:24	KAMEQIPLSY	0.9995	0.8188	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:12	KAMEQIPLSY	0.9994	0.6555	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B57:04	KAMEQIPLSY	0.9992	0.566	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:11	KAMEQIPLSY	0.9992	0.7823	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B57:10	KAMEQIPLSY	0.9992	0.8957	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C15:09	KAMEQIPLSY	0.9978	0.8529	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B58:06	KAMEQIPLSY	0.9977	0.6347	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:20	KAMEQIPLSY	0.9975	0.797	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:28	KAMEQIPLSY	0.9963	0.7998	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C03:02	KAMEQIPLSY	0.9941	0.9585	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:20	KAMEQIPLSY	0.9941	0.8079	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:77	KAMEQIPLSY	0.9938	0.7342	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:23	KAMEQIPLSY	0.9931	0.7238	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:30	KAMEQIPLSY	0.9865	0.6372	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:17	KAMEQIPLSY	0.9865	0.6372	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C01:03	YAPSKAMEQI	0.9851	0.9556	7	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C12:02	KAMEQIPLSY	0.9814	0.9431	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C12:03	KAMEQIPLSY	0.979	0.9702	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C01:02	YAPSKAMEQI	0.9731	0.9452	7	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C16:01	KAMEQIPLSY	0.9709	0.9603	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C16:02	KAMEQIPLSY	0.9547	0.9797	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C16:04	KAMEQIPLSY	0.9537	0.976	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C02:02	KAMEQIPLSY	0.9525	0.9479	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-C02:10	KAMEQIPLSY	0.9525	0.9479	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:09	THYAPSKAME	0.9282	0.6796	5	15
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-A32:01	KAMEQIPLSY	0.8931	0.8656	11	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:09	PTHYAPSKAM	0.1214	0.5804	4	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:22	SPTHYAPSKAM	0.9998	0.5978	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B07:09	SPTHYAPSKAM	0.9998	0.6159	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B48:02	SKAMEQIPLSY	0.9878	0.7542	10	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:54	SKAMEQIPLSY	0.9714	0.7211	10	21
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:11	SPTHYAPSKAM	0.949	0.6898	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B67:01	SPTHYAPSKAM	0.806	0.7429	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B82:02	SPTHYAPSKAM	0.7858	0.5056	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B35:09	SPTHYAPSKAM	0.7485	0.8133	3	14
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B67:01	APSKAMEQIPL	0.7132	0.7239	8	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	HLA-B15:09	SPTHYAPSKAM	0.454	0.5275	3	14

Top

Potential FusionNeoAntigen Information of PRKAG2-ACTR3C in HLA II

PRKAG2-ACTR3C_151372506_149946143.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0407	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0447	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0454	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0454	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0469	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0474	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0901	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0901	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0902	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0902	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0902	ASPTHYAPSKAMEQI	2	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0903	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0903	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0903	ASPTHYAPSKAMEQI	2	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0904	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0904	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0907	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0907	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0908	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0908	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0908	ASPTHYAPSKAMEQI	2	17
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0909	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB1-0909	PTHYAPSKAMEQIPL	4	19
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB5-0112	SPTHYAPSKAMEQIP	3	18
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	1189	DRB5-0112	PTHYAPSKAMEQIPL	4	19

Top

Fusion breakpoint peptide structures of PRKAG2-ACTR3C

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3553	HYAPSKAMEQIPLS	PRKAG2	ACTR3C	chr7	151372506	chr7	149946143	1189

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRKAG2-ACTR3C

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3553	HYAPSKAMEQIPLS	-7.15543	-7.26883
HLA-B14:02	3BVN	3553	HYAPSKAMEQIPLS	-4.77435	-5.80965
HLA-B52:01	3W39	3553	HYAPSKAMEQIPLS	-6.80875	-6.92215
HLA-B52:01	3W39	3553	HYAPSKAMEQIPLS	-4.20386	-5.23916
HLA-A11:01	4UQ2	3553	HYAPSKAMEQIPLS	-7.5194	-8.5547
HLA-A11:01	4UQ2	3553	HYAPSKAMEQIPLS	-6.9601	-7.0735
HLA-A24:02	5HGA	3553	HYAPSKAMEQIPLS	-7.52403	-7.63743
HLA-A24:02	5HGA	3553	HYAPSKAMEQIPLS	-5.82433	-6.85963
HLA-B27:05	6PYJ	3553	HYAPSKAMEQIPLS	-3.28285	-4.31815
HLA-B44:05	3DX8	3553	HYAPSKAMEQIPLS	-5.91172	-6.94702
HLA-B44:05	3DX8	3553	HYAPSKAMEQIPLS	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of PRKAG2-ACTR3C

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	10	19	SKAMEQIPL	TCCAAAGCCATGGAACAAATTCCACTG
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	10	21	SKAMEQIPLSY	TCCAAAGCCATGGAACAAATTCCACTGAGCTAT
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	11	21	KAMEQIPLSY	AAAGCCATGGAACAAATTCCACTGAGCTAT
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	12	21	AMEQIPLSY	GCCATGGAACAAATTCCACTGAGCTAT
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	3	14	SPTHYAPSKAM	TCACCGACACACTATGCTCCCTCCAAAGCCATG
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	4	14	PTHYAPSKAM	CCGACACACTATGCTCCCTCCAAAGCCATG
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	5	14	THYAPSKAM	ACACACTATGCTCCCTCCAAAGCCATG
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	5	15	THYAPSKAME	ACACACTATGCTCCCTCCAAAGCCATGGAA
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	6	14	HYAPSKAM	CACTATGCTCCCTCCAAAGCCATG
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	7	17	YAPSKAMEQI	TATGCTCCCTCCAAAGCCATGGAACAAATT
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	8	17	APSKAMEQI	GCTCCCTCCAAAGCCATGGAACAAATT
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	8	19	APSKAMEQIPL	GCTCCCTCCAAAGCCATGGAACAAATTCCACTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	2	17	ASPTHYAPSKAMEQI	GCATCACCGACACACTATGCTCCCTCCAAAGCCATGGAACAAATT
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	3	18	SPTHYAPSKAMEQIP	TCACCGACACACTATGCTCCCTCCAAAGCCATGGAACAAATTCCA
PRKAG2-ACTR3C	chr7	151372506	chr7	149946143	4	19	PTHYAPSKAMEQIPL	CCGACACACTATGCTCCCTCCAAAGCCATGGAACAAATTCCACTG

Top

Information of the samples that have these potential fusion neoantigens of PRKAG2-ACTR3C

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LIHC	PRKAG2-ACTR3C	chr7	151372506	ENST00000287878	chr7	149946143	ENST00000252071	TCGA-2Y-A9HA-01A

Top

Potential target of CAR-T therapy development for PRKAG2-ACTR3C

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PRKAG2-ACTR3C

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PRKAG2-ACTR3C

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)